logo
Plus   Neg
Share
Email

Merck's Keytruda Fails Late Stage Clinical Trial

Merck & Co. (MRK) Monday said its cancer treatment Keytruda failed to meet goals in another late-stage study.

Merck said the Phase 3 Keynote-119 trial evaluating Keytruda, Merck's monotherapy for the second- or third-line treatment of patients with metastatic triple-negative breast cancer did not meet its primary endpoint of superior overall survival compared to chemotherapy.

"Metastatic triple-negative breast cancer is an aggressive and challenging disease to treat, especially after progression on initial standard-of-care treatment," said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories.

"While we are disappointed by the outcome of this monotherapy trial, we are continuing to study KEYTRUDA in earlier stages of the disease and in combination with chemotherapy to address the unmet medical need of patients with triple negative breast cancer. We are grateful to the patients and investigators for their participation in this important study."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
A new research has found unusual increase in malware, as cyber criminals find new avenues to attack. WatchGuard Technologies on Tuesday released its quarterly Internet Security Report for first quarter. The report says malware detections in the first quarter surged a massive 62% from previous quarter. The... A study has suggested that the risk of dementia is stronger in older adults on the use of anticholinergic drugs, highlighting the importance of reducing exposure to anticholinergic drugs in middle-aged and older people. Anticholinergic drugs work by blocking the action of a neurotransmitter called acetylcholine. This inhibits nerve impulses responsible for involuntary muscle movements. Norway's $1 trillion sovereign wealth fund, the world's largest, has been given the approval to invest again in retail giant Walmart Inc. and miner Rio Tinto plc, among other companies. This follows the Norway central bank's decision to revoke these companies' exclusions from the fund's investments on ethical grounds. Walmart was excluded in 2006 from the pension fund's investments.
Follow RTT